FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approves a supplemental application for RYDAPT (midostaurin) from Novartis Pharmaceuticals; the update expands or modifies the drug’s label to include addit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Flt3 Mutation
• Aggressive Systemic Mastocytosis
• Mast Cell Leukemia
• Systemic Mastocytosis
• Systemic Mastocytosis with Associated Hematologic Neoplasm

Drugs mentioned

• Rydapt (midostaurin)

Snippet

SUPPL AP for RYDAPT (RYDAPT)